Results 221 to 230 of about 76,308 (284)
A bionic nanomedicine system with core–shell structure (Nm‐pAu/CP/KU) was constructed. PEGylated gold nanoparticles (pAu) were loaded with cisplatin (CP) and a radiochemotherapy sensitizer (KU‐60019) to form the core pAu/CP/KU, and homologous nasopharyngeal carcinoma cell membrane vesicles (Nm) were used as the shell.
Junhua Zhang +4 more
wiley +1 more source
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan +9 more
wiley +1 more source
Cyclin-dependent kinase 5 is required for normal cerebellar development
Ayumi Kumazawa +9 more
openalex +2 more sources
ABSTRACT Background Lichen sclerosus is a chronic, inflammatory, scarring disease of the skin that manifests mostly in the genital region. Objective We studied the histomorphological characteristics, grade, and pattern of inflammation in male pediatric patients with lichen sclerosus.
Valerie Flammang +10 more
wiley +1 more source
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann +12 more
wiley +1 more source
TrkA abundance is increased in cutaneous nerves in bortezomib‐induced neuropathy
Cutaneous nerves in bortezomib‐induced peripheral neuropathy (BIPN) show reduced nerve fiber density, increased TrkA expression, and enhanced dermal angiogenesis, highlighting a pathological switch in NGF/TrkA signaling that may contribute to nerve damage and pain. Abstract Tropomyosin receptor kinase A (TrkA), a high‐affinity receptor for nerve growth
Yuying Jin +14 more
wiley +1 more source

